Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai, 200032, People's Republic of China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Surg Endosc. 2018 Mar;32(3):1441-1448. doi: 10.1007/s00464-017-5830-4. Epub 2017 Sep 15.
Although endoscopic resection (ER) may be sufficient treatment for early-stage esophageal cancer, additional treatment is recommended when there is a high risk of cancer recurrence. It is unclear whether delaying esophagectomy by performing and assessing the success of ER affects outcomes as compared with immediate esophagectomy without ER. Additionally, long-term survival after sequential ER and esophagectomy required further investigation.
Between 2011 and 2015, 48 patients with stage T1 esophageal cancer underwent esophagectomy after ER with curative intent at our institution. Two-to-one propensity score methods were used to identify 96 matched-control patients who were treated with esophagectomy only using baseline patient, tumor characteristics and surgical approach. Time from initial evaluation to esophagectomy, relapse-free survival, overall survival, and postoperative complications were compared between the propensity-matched groups.
In the ER + esophagectomy group, the time from initial evaluation to esophagectomy was significantly longer than in the esophagectomy only group (114 vs. 8 days, p < 0.001). The incidence of dense adhesion (p = 0.347), operative time (p = 0.867), postoperative surgical complications (p = 0.966), and postoperative length of hospital stay (p = 0.125) were not significantly different between the groups. Moreover, recurrence-free survival and overall survival were also similar between the two groups (p = 0.411 and p = 0.817, respectively).
Treatment of stage T1 esophageal cancer with ER prior to esophagectomy did not increase the difficulty of performing esophagectomy or the incidence of postoperative complications and did not affect survival after esophagectomy. These results suggest that ER can be recommended for patients with stage T1 cancer even if esophagectomy is warranted eventually.
尽管内镜下切除术(ER)可能足以治疗早期食管癌,但如果存在癌症复发的高风险,建议进行额外的治疗。目前尚不清楚与不进行 ER 而直接进行食管切除术相比,通过进行 ER 并评估其成功与否来延迟食管切除术是否会影响结果。此外,还需要进一步研究 ER 序贯治疗和食管切除术后的长期生存情况。
在 2011 年至 2015 年间,我们机构对 48 例具有 T1 期食管癌的患者进行了以治愈为目的的 ER 治疗后食管切除术。使用二比一倾向评分法,对 96 例仅接受食管切除术的匹配对照患者进行了匹配,这些患者基于基线患者、肿瘤特征和手术方法进行了治疗。比较了两组患者从初始评估到食管切除术的时间、无复发生存率、总生存率和术后并发症。
在 ER+食管切除术组中,从初始评估到食管切除术的时间明显长于仅食管切除术组(114 天 vs. 8 天,p<0.001)。两组患者之间的致密粘连发生率(p=0.347)、手术时间(p=0.867)、术后手术并发症(p=0.966)和术后住院时间(p=0.125)差异均无统计学意义。此外,两组患者的无复发生存率和总生存率也相似(p=0.411 和 p=0.817)。
在进行食管切除术前对 T1 期食管癌进行 ER 治疗不会增加食管切除术的难度或术后并发症的发生率,也不会影响食管切除术后的生存。这些结果表明,即使最终需要进行食管切除术,ER 也可以推荐用于 T1 期癌症患者。